COVID-19 vaccine prioritisation for type 1 and type 2 diabetes

[1]  B. Bell,et al.  The Advisory Committee on Immunization Practices’ Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020 , 2021, MMWR. Morbidity and mortality weekly report.

[2]  C. Fischbacher,et al.  Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland , 2020, The Lancet Diabetes & Endocrinology.

[3]  E. Rubin,et al.  Audio Interview: SARS-CoV-2 Vaccination and Vulnerable Populations. , 2020, The New England journal of medicine.

[4]  A. McCoy,et al.  COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic’s Impact in Type 1 and Type 2 Diabetes , 2020, Diabetes Care.

[5]  K. Khunti,et al.  First-line treatment for type 2 diabetes: is it too early to abandon metformin? , 2020, The Lancet.

[6]  C. Mathieu,et al.  Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. , 2020, The lancet. Diabetes & endocrinology.

[7]  D. Maahs,et al.  COVID-19 and Children With Diabetes—Updates, Unknowns, and Next Steps: First, Do No Extrapolation , 2020, Diabetes Care.

[8]  K. Khunti,et al.  Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study , 2020, The Lancet Diabetes & Endocrinology.

[9]  D. Jun,et al.  Increasing comorbidities in a South Korea insured population‐based cohort of patients with chronic hepatitis B , 2020, Alimentary pharmacology & therapeutics.

[10]  B. Lewis,et al.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD , 2020 .

[11]  C. Mathieu,et al.  2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2019, Diabetes Care.

[12]  B. Zinman,et al.  Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy? , 2019, Diabetes, obesity & metabolism.

[13]  K. Mahaffey,et al.  Abstract #259 Cardiovascular and Renal Outcomes with Canagliflozin in People with Type 2 Diabetes According to Baseline use of Metformin , 2019, Endocrine Practice.

[14]  G. Dusheiko,et al.  Advancing Age and Comorbidity in a US Insured Population‐Based Cohort of Patients With Chronic Hepatitis B , 2019, Hepatology.

[15]  S. Alavian,et al.  Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. , 2018, The lancet. Gastroenterology & hepatology.

[16]  B. McMahon,et al.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.

[17]  J. Eisman,et al.  Mortality after all major types of osteoporotic fracture in men and women: an observational study , 1999, The Lancet.

[18]  O. Johnell,et al.  Long-Term Risk of Osteoporotic Fracture in Malmö , 2000, Osteoporosis International.